Median baseline parameters across the total cohort and male and female populations.

<p>Median baseline parameters across the total cohort and male and female populations.</p

Prevalence data and standard error per participating country.

<p>Graphs depicting (A) dyslipidemia prevalence, (B) hypertension prevalence, (C) obesity (defined by BMI ≥30 kg/m²) prevalence, (D) abdominal obesity prevalence, (E) diabetes prevalence, and (F) smoking prevalence. Overall prevalence is shown by a solid line.</p

Overall cohort prevalence per investigated cardiovascular risk factor.

<p>Graphs to show the difference in total cohort prevalence data for each risk factor (dyslipidemia, hypertension, diabetes, obesity (defined by BMI ≥30 kg/m²), abdominal obesity, and smoking) by (A) age, (B) gender, and (C) location.</p

Overall prevalence of cardiovascular risk factors across all participating countries.

<p>Graph to show the overall prevalence and standard error of dyslipidemia, hypertension, obesity (defined by BMI ≥30 kg/m²), abdominal obesity, diabetes, and smoking across the AfME region.</p

Proportion of outpatients presenting with one or more cardiovascular risk factors.

<p>Graph to show the percentage of outpatients presenting with 1–6 CV risk factors. Risk factors: dyslipidemia prevalence, hypertension prevalence, obesity (defined by BMI ≥30 kg/m²) prevalence, abdominal obesity prevalence, diabetes prevalence, and smoking prevalence.</p

Comparison of atrial fibrillation risk factors between sexes.

<p>Comparison of atrial fibrillation risk factors between sexes.</p

Baseline characteristics of study patients with non-valvular atrial fibrillation^*.

<p>Baseline characteristics of study patients with non-valvular atrial fibrillation^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0175405#t001fn002" target="_blank">*</a>}.</p

Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).

<p>Sex differences in outcome events at 12 months follow-up in the entire cohort according to the reasons for emergency room visit (N = 2043).</p

Comparison of differences in CHADS₂ with warfarin and antiplatelet therapy between sexes (n = 1776).

<p>Comparison of differences in CHADS₂ with warfarin and antiplatelet therapy between sexes (n = 1776).</p

Baseline characteristics of patients stratified by gender (n = 7930).

<p>Figures in parentheses are percentages and continuous variables are shown as mean±SD.</p><p>Abbreviations: SD, standard deviation; BMI, body mass index; CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous coronary intervention; CABG, coronary artery bypass graft; CHF, congestive heart failure; STEMI, ST elevation myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina.</p>*<p>Killip class (scale I–IV) a system used to stratify the severity of left ventricular dysfunction and determines clinical status of patients post myocardial infarction (MI).</p><p>Killip classification:</p><p>Class 1: No rales, no 3rd heart sound.</p><p>Class 2: Rales in <1/2 lung field or presence of a 3rd heart sound.</p><p>Class 3: Rales in >1/2 lung field–pulmonary edema.</p><p>Class 4: Cardiogenic shock–determined clinically.</p